Goel, Leela http://orcid.org/0000-0002-5210-4579
Wu, Huaiyu
Zhang, Bohua http://orcid.org/0000-0002-9329-0507
Kim, Jinwook
Dayton, Paul A.
Xu, Zhen
Jiang, Xiaoning http://orcid.org/0000-0003-3605-3801
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HL141967, R01HL141967, R01HL141967, R01HL141967, R01HL141967, R01HL141967, R01HL141967)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 21 October 2020
Revised: 13 November 2020
Accepted: 27 November 2020
First Online: 6 January 2021
Competing interests
: Xiaoning Jiang has financial interest in Sonovascular, Inc. who licensed an intravascular sonothrombolysis technology from NC State. Paul Dayton is an inventor on several patents, describing the low-boiling point phase change nanodroplets described here, and is a co-founder of Triangle Biotechnology, Inc., which has licensed these patents. Zhen Xu has financial interest in HistoSonics.